Citations

Clear

17 citation(s) found for "Dinu, Valentin".

Accurate Identification of Subclones in Tumor Genomes
Ahmadinejad, Navid , Troftgruben, Shayna, Wang, Junwen , Chandrashekar, Pramod Bharadwaj , Dinu, Valentin , Maley, Carlo C. , Liu, Li , Chandrashekar, Pramod B , Maley, Carlo C. , Dinu, Valentin , Wang, Junwen , Liu, Li

Mayo Clinic

Molecular Biology and Evolution | June 24, 2022 | Volume: 39 | Issue: 7 | Pages: No page available

10.1093/molbev/msac136 | PMID 35749590 Get It

AbstractUnderstanding intratumor heterogeneity is critical for studying tumorigenesis and designing personalized treatments. To decompose the mixed cell population in a tumor, subclones are inferred computationally based on variant allele frequency (VAF) from bulk sequencing data. In this study, we showed that sequencing depth, mean VAF, and variance of VAF of a subclone are confounded. Without considering this effect, current methods require deep-sequencing data (>300× depth) to reliably infer subclones. Here, we present a novel algorithm that incorporates depth-variance and mean-variance dependencies in a clustering error model and successfully identifies subclones in tumors sequenced at depths of as low as 30×. We implemented the algorithm as a model-based adaptive grouping of subclones (MAGOS) method. Analyses of computer simulated data and empirical sequencing data showed that MAGOS outperformed existing methods on minimum sequencing depth, decomposition accuracy, and computation efficiency. The most prominent improvements were observed in analyzing tumors sequenced at depths between 30× and 200×, whereas the performance was comparable between MAGOS and existing methods on deeply sequenced tumors. MAGOS supports analysis of single-nucleotide variants and copy number variants from a single sample or multiple samples of a tumor. We applied MAGOS to whole-exome data of late-stage liver cancers and discovered that high subclone count in a tumor was a significant risk factor of poor prognosis. Lastly, our analysis suggested that sequencing multiple samples of the same tumor at standard depth is more cost-effective and robust for subclone characterization than deep sequencing a single sample. MAGOS is available at github (https://github.com/liliulab/magos).
Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes
Balanescu, Dinu Valentin , Bloomingdale, Richard , Yang, Eric H. , Iliescu, Cezar , Herrmann, Joerg , Yang, Eric , Balanescu, Dinu V , Donisan, Teodora , Parwani, Purvi , Hanson, Ivan

Mayo Clinic

Reviews in Cardiovascular Medicine | June 24, 2022 | Volume: 23 | Issue: 7 | Pages: No page available

10.31083/j.rcm2307227 | PMID 39076910 Get It

In patients with cancer, myocardial infarction (MI) has distinct features and mechanisms compared to the non-oncology population. Triggers of myocardial ischemia specific to the oncology population have been increasingly identified. Coronary plaque disruption, coronary vasospasm, coronary microvascular dysfunction, spontaneous coronary artery dissection, and coronary oxygen supply-demand mismatch are all causes of MI that have been shown to have specific triggers related to either the treatments or complications of cancer. MI can occur in the presence or absence of atherosclerotic coronary artery disease (CAD). MI with nonobstructive CAD (MINOCA) is a heterogeneous syndrome that has distinct pathophysiology and different epidemiology from MI with significant CAD (MI-CAD). Recognition and differentiation of MI-CAD and MINOCA is essential in the oncology population, due to unique etiology and impact on diagnosis, management, and overall outcomes. There are currently no reports in the literature concerning MINOCA as a unified syndrome in oncology patients. The purpose of this review is to analyze the literature for studies related to known triggers of myocardial ischemia in cancer patients, with a focus on MINOCA. We propose that certain cancer treatments can induce MINOCA-like states, and further research is warranted to investigate mechanisms that may be unique to certain cancer states and types of treatment.
P1253Clinical features and outcomes of patients with chemotherapy-induced Takotsubo stress cardiomyopathy
Liu, V Y, Donisan, Teodora , Agha, Ali , Giza, Dana Elena , Iliescu, Gloria, Kim, P Y, Boone, David L., Herrmann, Joerg , Marmagkiolis, Kostas, Angelini, Paolo , Iliescu, Cezar , Balanescu, Dinu Valentin , Lopez‐Mattei, Juan , Palaskas, Nicolas L , Boone, D L, Yang, Eric H.

Mayo Clinic

European Heart Journal | December 10, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p1253 Get It

Dispersion analysis of PoTRA ranked mRNA mediated dysregulated pathways in Breast Invasive Cancer from a TCGA Pan-Cancer study
Linan, Margaret, Dinu, Valentin

Mayo Clinic

No container title available | October 30, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27306v1 Get It

Background. Our publication of the new pathways of topological rank analysis (PoTRA) algorithm demonstrated a novel approach for using the Google Search PageRank algorithm to analyze gene expression networks to identify biological pathways significantly disrupted in hepatocellular carcinoma. In order to apply the PoTRA algorithm to analyze other cancer gene expression data sets, of various sizes and normal:tumor ratio composition, two important questions must be answered: 1. What is the optimal normal:tumor sample ratio?; and 2. What is the minimum number of samples that should be used for PoTRA analysis? To address these questions, the average standard deviation (SD) in PoTRA-ranked mRNA mediated dysregulated pathways was studied using randomly sampled data sets with various normal:tumor ratios and sizes drawn from the TCGA Breast Invasive Carcinoma (TCGA-BRCA) project. Methods. To identify the optimal normal:tumor sample ratios, the SD analysis used random combinations of 1:N unbalanced normal:tumor data sets: (1:1, 1:2, 1:3, 1:5, 1:7, 1:9). To identify the minimum sample size, random resampling of normal and tumor samples of various sizes are used: (3 vs 3), (5 vs 5), (10 vs 10), (25 vs 25), (50 vs 50), (75 vs 75), (100 vs 100), and (113 vs 113). Results. This analysis suggests that the 1:1 ratio achieves the lowest average rank variation and that the minimum sample size of 50 normal and 50 tumor samples reaches a steady state in the average rank variation. Conclusion. In conclusion, future applications of the PoTRA algorithm to analyze gene expression data sets such as TCGA should use balanced data sets as well as a minimum sample size of 50 for both normal and tumor to ensure the most robust performance.
Clinical outcomes after fractional flow reserve-guided treatment of oncology patients.
Dayah, Tariq, Balanescu, Dinu Valentin , Karimzad, Kaveh , Boone, David L., Kim, Peter , Durand, Jean‐Bernard , Herrmann, Joerg , Marmagkiolis, Konstantinos , Johnson, Nils P. , Iliescu, Cezar , Balanescu, Dinu V , Donisan, Teodora , Boone, David L, Lopez‐Mattei, Juan , Yang, Eric H.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22106-e22106

10.1200/jco.2018.36.15_suppl.e22106 Get It

The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation
Kocher, Jean-Pierre A., Quest, Daniel, Meiners, Michael A., Moore, Raymond M. , Hossain, Asif, Hart, Steven N. , Dinu, Valentin , Quest, Daniel J, Duffy, Patrick, Rider, David, Duffy, Patrick Emmet , Rider, David A. , Dinu, Valentin , Hart, Steven N , Moore, Raymond

Mayo Clinic

Bioinformatics | March 12, 2014 | Volume: 30 | Issue: 13 | Pages: 1920-1922

10.1093/bioinformatics/btu137 | PMID 24618464 Get It

Abstract Motivation: The Biological Reference Repository (BioR) is a toolkit for annotating variants. BioR stores public and user-specific annotation sources in indexed JSON-encoded flat files (catalogs). The BioR toolkit provides the functionality to combine and retrieve annotation from these catalogs via the command-line interface. Several catalogs from commonly used annotation sources and instructions for creating user-specific catalogs are provided. Commands from the toolkit can be combined with other UNIX commands for advanced annotation processing. We also provide instructions for the development of custom annotation pipelines. Availability and implementation: The package is implemented in Java and makes use of external tools written in Java and Perl. The toolkit can be executed on Mac OS X 10.5 and above or any Linux distribution. The BioR application, quickstart, and user guide documents and many biological examples are available at http://bioinformaticstools.mayo.edu . Contact: Kocher.JeanPierre@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
AMASS: a database for investigating protein structures
Mielke, Clinton, Mandarino, Lawrence J. , Dinu, Valentin , Mielke, Clinton J, Dinu, Valentin

Mayo Clinic

Bioinformatics | February 5, 2014 | Volume: 30 | Issue: 11 | Pages: 1595-1600

10.1093/bioinformatics/btu073 | PMID 24497503 Get It

Abstract Motivation: Modern techniques have produced many sequence annotation databases and protein structure portals, but these Web resources are rarely integrated in ways that permit straightforward exploration of protein functional residues and their co-localization. Results: We have created the AMASS database, which maps 1D sequence annotation databases to 3D protein structures with an intuitive visualization interface. Our platform also provides an analysis service that screens mass spectrometry sequence data for post-translational modifications that reside in functionally relevant locations within protein structures. The system is built on the premise that functional residues such as active sites, cancer mutations and post-translational modifications within proteins may co-localize and share common functions. Availability and implementation: AMASS database is implemented with Biopython and Apache as a freely available Web server at amass-db.org. Contact: clinton.mielke@gmail.com